Cart
sales@molnova.com
Home - Products - Angiogenesis - c-Met/HGFR - JUN04542

JUN04542

CAS No. 2367004-54-2

JUN04542( CL-092 )

Catalog No. M24079 CAS No. 2367004-54-2

JUN04542 is an Axl Mer cMet KDR inhibitor for the treatment of Axl and Mer receptor tyrosine kinase- dependent disorders.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 47 In Stock
2MG 29 In Stock
5MG 41 In Stock
10MG 69 In Stock
25MG 129 In Stock
50MG 207 In Stock
100MG 345 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock
Get Quotation Bulk Inquiry Add to Cart

Biological Information

  • Product Name
    JUN04542
  • Note
    Research use only, not for human use.
  • Brief Description
    JUN04542 is an Axl Mer cMet KDR inhibitor for the treatment of Axl and Mer receptor tyrosine kinase- dependent disorders.
  • Description
    JUN04542 is an Axl Mer cMet KDR inhibitor for the treatment of Axl and Mer receptor tyrosine kinase- dependent disorders.
  • In Vitro
    ——
  • In Vivo
    Animal Model:Rat Dosage:3 mg/kg (Pharmacokinetic Analysis) Administration:IV Result:Had a T1/2 of 5.4 hours, a CL of 43 mL/hr?kg.
  • Synonyms
    CL-092
  • Pathway
    Angiogenesis
  • Target
    c-Met/HGFR
  • Recptor
    Axl|c-Met|KDR|Mer
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2367004-54-2
  • Formula Weight
    528.53
  • Molecular Formula
    C29H25FN4O5
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:10 mM
  • SMILES
    CNC(=O)C1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Lynne Canne Bannen, Minna Bui, Faming Jiang, et al Compounds for the treatment of kinase-dependent disorders;WO 2019148044
Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog
related products

  • JNJ-38877618

    JNJ-38877618 (OMO-1) is a novel potent, highly selective, orally bioavailable c-Met tyrosine kinase inhibitor.

  • Amivantamab

    Amivantamab (JNJ-61186372) is a humanized antibody that recognizes epidermal growth factor receptor (EGFR) and MET proto-oncogene (MET).

  • MK-8033

    MK-8033 is a potent, specific, dual c-Met/Ron kinases inhibitor with IC50 of 1/7 nM.

Sign In Join Free